ArticleFrontiers in cardiovascular medicine2025
Neutrophil-lymphocyte ratio and subclinical atherosclerosis in essential hypertensive patients.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Asymmetric Dimethylarginine as an Integrative Biomarker of Endothelial, Cardiometabolic and Hepatic Dysfunction in Stable Coronary Artery Disease.Biomedicines · 2026Article
- Association of Inflammatory-Hematological Biomarkers with Hypertension and Related Comorbidities.Journal of clinical medicine · 2026Article
- Lower serum SFRP5 levels are associated with carotid atherosclerosis in patients with essential hypertension.American journal of translational research · 2026Article
- Association between monocyte-to-lymphocyte ratio and metabolic dysfunction-associated steatotic liver disease and hepatic steatosis: evidence from NHANES 2017-2020.Translational gastroenterology and hepatology · 2026Article
- Association Between the Aggregate Index of Systemic Inflammation and Non-Dipper Blood Pressure Pattern in Hypertensive Patients with Type 2 Diabetes Mellitus.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Arterial hypertension plays a significant role in promoting organ damage and the development of atherosclerosis. The neutrophil-lymphocyte ratio (NLR) is an accessible and cost-effective biomarker that has been strongly associated with adverse outcomes in patients with coronary artery disease and chronic heart failure. The aim of this study was to evaluate the clinical utility of NLR as a surrogate biomarker of subclinical atherosclerotic damage in patients with essential hypertension. Methods: From January 2024 to November 2024, we consecutively enrolled 346 patients with essential hypertension. For all patients, we collected medical history, anthropometric data, biochemical analyses, and subclinical organ damage, including 24-h urinary excretion of microalbuminuria, carotid intima-media thickness, and transthoracic echocardiography. We excluded patients with arterial hypertension, coronary artery disease, or cerebrovascular or peripheral artery disease. Results: In our study, we found that patients with higher NLR were associated with high blood pressure values, the use of more than three antihypertensive medications, and a higher prevalence of dyslipidemia and obstructive sleep apnea syndrome. Moreover, elevated NLR values correlated with a higher prevalence of subclinical organ damage (left cardiac ventricular mass, carotid atherosclerosis, and increased microalbuminuria). Conclusions: Our study shows that in patients with essential hypertension, NLR is significantly correlated with some cardiovascular comorbidities and subclinical organ damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.